New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 1,170
Revenue ttm —
Net income ttm (287)
Free cash flow ttm (227)
Net debt Q (472)
Valuation
P/E n/m
Forward P/E e —
Price / sales —
Forward P/S e Powerpack
Price / FCF n/m
Price / book 1.9
Financial health
Current ratio Q 10.6 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth e —
EPS growth e —
EPS growth e —
EPS growth, 5 yrs e —
Insiders
Net bought 12m 90
Sells 12m 0
Buys 12m 3
Owned by insiders 30.5%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Valuation

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — 0 1 +66.7%
Gross margin, % — — — — — — — — — — — —
EBT — — — — — — — — (89) (196) (288) n/m
EBT margin, % — — — — — — — — — — — —
Net income — — — — — — — — (89) (192) (287) n/m
Per share, $
Per share, $ Revenue — — — — — — — — — — — —
Earnings — — — — — — — — (8.79) (14.84) (13.33) n/m
Cash flow — — — — — — — — (1.87) (11.68) (2.38) n/m
Capex — — — — — — — — (0.18) (0.40) (0.09) +122.1%
Free cash flow — — — — — — — — (2.05) (12.07) (2.46) n/m
Book value — — — — — — — — (8.25) (19.35) 6.22 n/m
Shares, m — — — — — — — — 10 13 36 +28.3%
Valuation, ×
Valuation, × P/E — — — — — — — — — — n/m —
P/S — — — — — — — — — — — —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — — —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — (19) (151) (219) n/m
Capex — — — — — — — — (2) (5) (8) +184.9%
Free cash flow — — — — — — — — (21) (156) (227) n/m
Balance, $m
Balance, $m Working capital — — — — — — — — 42 308 439 +632.3%
Net debt — — — — — — — — (49) (335) (472) n/m
Shareholders’ equity — — — — — — — — (83) (250) 573 n/m
Returns, %
Returns, % ROA — — — — — — — — — (84.47) (80.59) —
ROIC — — — — — — — — 0.00 0.00 (187.24) 0.0 pt
ROE — — — — — — — — — 115.10 (117.38) —
People
People Employees — — — — — — — — — 241 — —
Revenue/emp, $m — — — — — — — — — — — —
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated Nov 18, 2026

KARDIGAN INC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MLYS Mineralys Therapeutics, Inc. $1.3B — (loss-making) — — n/m −49.27% (below 0%: shrinking) — — Compare
SLN Silence Therapeutics PLC Sponsored ADR $1.2B — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m −17.28% (below 0%: shrinking) 97.39% (3,729.15%) Compare
GPCR Structure Therapeutics Inc. Sponsored ADR $1.2B — (loss-making) — — n/m −100.40% (below 0%: shrinking) 0.00% — Compare
SVRA Savara Inc. $1.2B — (loss-making) — (loss-making) — n/m −90.03% (below 0%: shrinking) 0.00% (1,301,100.00%) Compare
KARD KARDIGAN INC $1.2B — (loss-making) — — n/m −28.61% (below 0%: shrinking) — —
AAPG Ascentage Pharma Group International - Unsponsored ADR $1.2B — — — — — — — Compare
VOR Vor Biopharma Inc. $1.1B — (loss-making) — — n/m −47.59% (below 0%: shrinking) — — Compare
NKTR Nektar Therapeutics $1.1B — (loss-making) — (loss-making) −20.39% (below 0%: shrinking) n/m −47.99% (below 0%: shrinking) 100.00% (615.83%) Compare
INBX Inhibrx Biosciences, Inc. $1.1B — (loss-making) — (loss-making) — n/m −2.29% (below 0%: shrinking) 100.00% (1,586.75%) Compare
Median of peers $1.2B — — — — −47.99% 97.39% (2,657.95%)

All 621 Biotechnology stocks →

stockrow.com/KARD · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com